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Abstract
ZBED6 is a recently discovered transcription factor, unique to placental mammals, that has evolved from a domesticated
DNA transposon. It acts as a repressor at the IGF2 locus. Here we show that ZBED6 acts as a transcriptional modulator in
mouse myoblast cells, where more than 700 genes were differentially expressed after Zbed6-silencing. The most significantly
enriched GO term was muscle protein and contractile fiber, which was consistent with increased myotube formation.
Twenty small nucleolar RNAs all showed increased expression after Zbed6-silencing. The co-localization of histone marks and
ZBED6 binding sites and the effect of Zbed6-silencing on distribution of histone marks was evaluated by ChIP-seq analysis.
There was a strong association between ZBED6 binding sites and the H3K4me3, H3K4me2 and H3K27ac modifications,
which are usually found at active promoters, but no association with the repressive mark H3K27me3. Zbed6-silencing led to
increased enrichment of active marks at myogenic genes, in agreement with the RNA-seq findings. We propose that ZBED6
preferentially binds to active promoters and modulates transcriptional activity without recruiting repressive histone
modifications.
Citation: Jiang L, Wallerman O, Younis S, Rubin C-J, Gilbert ER, et al. (2014) ZBED6 Modulates the Transcription of Myogenic Genes in Mouse Myoblast Cells. PLoS
ONE 9(4): e94187. doi:10.1371/journal.pone.0094187
Editor: Roberto Mantovani, Universita` degli Studi di Milano, Italy
Received April 29, 2013; Accepted March 12, 2014; Published April 8, 2014
Copyright:  2014 Jiang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by grants from the Swedish Research Council and Swedish Foundation for Strategic Research. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: leif.andersson@imbim.uu.se
¤ Current address: Department of Animal and Poultry Sciences, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America
Introduction
ZBED6 was recently discovered as a novel transcriptional
repressor of IGF2 because a mutation disrupting one of its binding
sites in porcine IGF2 intron 3 leads to greater postnatal IGF2
expression in skeletal and cardiac muscle and makes pigs grow
more muscle and a bigger heart [1,2]. The ZBED6 protein
contains two putative zinc-finger BED domains, named after the
chromatin-boundary-element-binding proteins BEAF and DREF
[3], and a hAT dimerization domain, a feature characteristic of
the hobo-Ac-Tam3 transposase superfamily [4]. ZBED6 is unique to
placental mammals and has evolved from a domesticated DNA
transposon. It appears to have evolved an essential function after
the split between marsupials and placental mammals but before
the radiation of placental mammals [1,5]. The primary amino acid
sequence of ZBED6, in particular the region comprising the DNA
binding BED domains (residues 129–183 and 266–318), is highly
conserved among all placental mammals for which sequence
information is available (.26 species).
ZBED6 contains one nucleolar localization signal (residues 61–
80), which targets ZBED6 protein into the nucleolus [1]. This
lysine- and arginine-rich signal sequence is positively charged and
extremely conserved among 26 placental mammals. This suggests
that the nucleolar localization of ZBED6 is important for its
function. The nucleolus is the site for ribosomal RNA (rRNA)
synthesis, rRNA processing through small nucleolar ribonucleo-
proteins (snoRNPs) and ribosome assembly with ribosomal
proteins [6]. A number of transcriptional regulators including
MyoD and Myogenin repress rDNA transcription in the nucleolus
during myogenesis of C2C12 cells [7].
ChIP-sequencing using mouse myoblast-derived C2C12 cells
and an anti-ZBED6 antibody revealed approximately 2,500
putative ZBED6 binding sites [1], and 1,200 genes, including
Igf2, contained one or several putative ZBED6 binding sites within
5 kb of the defined transcription start site (TSS). It remains to be
shown to what extent ZBED6 regulates these genes and whether
ZBED6 always acts as a repressor or if it functions as a
transcriptional activator at some binding sites. Silencing of ZBED6
in C2C12 cells leads to an up-regulation of Igf2 mRNA expression
and enhanced cell growth, as well as enhanced myotube formation
during differentiation [1]. Mild ZBED6 overexpression, on the
other hand, leads to growth retardation in C2C12 cells [8].
The underlying pathways leading to changes in myotube
formation, the mechanism for ZBED6-mediated transcriptional
repression and the importance of ZBED6 in regulating targets
other than IGF2 are important questions that remain to be
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explored. Here, we used small interfering RNA (siRNA) to
suppress Zbed6 expression in mouse myoblasts, and studied the
effect of silencing on global gene expression by RNA-seq and used
microarrays to validate differential expression. Furthermore, we
integrated expression data with ZBED6 ChIP-seq data, transcrip-
tion factor binding, and performed ChIP-seq for histone
modifications before and after silencing to investigate the
regulatory mechanisms of Zbed6.
Results
Zbed6-silencing in mouse myoblast cells
The Zbed6-silencing experiment was performed by transfecting
C2C12 cells with a pool of Zbed6 siRNAs. We used two different
time points for analysis, two and four days post-transfection, and
used a pool of scrambled siRNAs as a negative control. The
silencing of Zbed6 mRNA expression was verified by quantitative
PCR. Zbed6 mRNA was reduced by more than 70% and 50% on
days 2 and 4, respectively (Figure 1A). ZBED6 protein level was
efficiently suppressed on day 2, as verified by western blotting
(Figure 1B). In addition, suppression of ZBED6 resulted in
increased expression of its well-known target Igf2, starting on day 2
and reaching at least a 2.5- fold increase on day 4 (Figure 1A),
consistent with our previous finding [1]. In summary, we
efficiently silenced Zbed6 in mouse myoblast cells and the level of
silencing was sufficient to change the expression of downstream
targets.
Global effects of Zbed6-silencing measured by RNA-seq
and expression arrays
We performed triplicate Zbed6 silencing experiments in C2C12
cells to prepare RNA for expression profiling with SOLiD strand-
specific RNA sequencing and further used Illumina BeadChip
arrays to validate the main results from the RNA-seq analysis. For
RNA-seq, replicates were pooled and the sequencing gave 21–25
million uniquely aligned 50-bp reads per time point and sample
(Table S1), of which 75% were mapped to known exons. By
directly comparing read counts from the Zbed6-silenced samples
with control samples across the Zbed6 and Igf2 genomic regions, we
could verify a decreased expression of Zbed6 and an increased
expression of Igf2 at both time points as expected (Figure 1C).
We calculated the gene expression in RPKM (reads per kilobase
of exon per million mapped reads) using a gene model based on
Ensembl annotations (see Methods). The detection threshold for
the RNA-seq analysis was set to an RPKM value of at least 1 in at
least one of the four samples. One RPKM has previously been
estimated to equal one transcript per C2C12 cell [9]. We detected
13,344 (35.6%) out of the 37,515 annotated Ensembl genes in at
least one sample using this criterion. Most genes were expressed
with less than 100 copies per cell and only 82 (0.6%) expressed
more than 500 copies per cell (Figure S1).
Differential expression (DE) between Zbed6-silenced and control
samples was calculated using DEGseq [10] with a false discovery
rate (FDR) of 0.001 and a fold change of 1.5 or higher. This gave
1,094 DE genes on day 2 and 4,412 on day 4. The correlation
between RNA-seq fold changes computed on the data from day 2
versus that from day 4 was highly significant (r = 0.50, P,10216,
Figure S2A). Thus, most genes had the same direction of
expression change from day 2 to day 4 after Zbed6-silencing. We
reasoned that genes that show the same change of expression on
both time points are less likely to be false positive and that the
larger number of DE genes at the later timepoint indicates more
secondary effects, thus we decided to focus on the DE genes at day
2 and also required the same direction of change between day 2
and day 4 for the definition of genes with significant differential
expression. We thereby identified 780 DE genes after Zbed6-
silencing in C2C12 cells.
In the microarray analysis, 8,537 (44.6%) out of 19,100 unique
Ensembl genes present on the array were detected as being
expressed. More than half of the DE genes (412/780) were either
not identified as expressed or not present on the array. A large
fraction (40%) of these genes belongs to different classes of non-
coding RNAs, pseudogenes and hypothetical proteins that are not
well represented on the array, and the remaining genes were on
average more lowly expressed than the genes detected by both
platforms (56% versus 69% had a RPKM,15, Table S2). The
fold changes measured by RNA-seq and arrays were strongly
correlated for the 368 DE genes that were detected with both
methods (r = 0.56, P,0.001). About one third of these genes had a
significant change in the same direction on the array (multiple test-
adjusted P,0.05). The overlap of DE genes was lower for lowly
expressed transcripts compared to those with medium or high
expression (30% and 35%, respectively). This comparison strongly
indicated that RNA-seq generated robust and reliable data and
these have been used for the following analyses.
In total we found 20 small nucleolar RNA genes that were
differentially expressed and strikingly, all of these genes were up-
regulated after Zbed6-silencing at both time-points (Table 1). The
up-regulation of the small nucleolar RNA genes was further
confirmed by qPCR. Three of the five randomly selected genes
showed up-regulation after Zbed6-silencing by qPCR and for two
of these genes the change in RNA levels were statistically
significant (P,0.05, Table 1).
We further validated the expression changes for six protein-
coding genes with low or medium expression (Fgf11, Nfkbil1,
Myo5a, Nr4a1, Sfrp2 and Ddit4) and one highly expressed long
noncoding RNA (H19) by qPCR. The fold changes measured by
RNA-seq and qPCR were significantly correlated (r = 0.84, P,
0.001). All seven genes showed consistent direction of change
between qPCR and RNA-seq, with significant qPCR values for all
except Ddit4 (Student’s t-test, P,0.05, Table S3).
Genes encoding muscle proteins were significantly over-
represented among the DE genes
The 780 DE genes were submitted for an enrichment analysis of
Gene Ontology terms and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) (see Methods).
We found highly significant enrichment for GO categories
representing muscular functions, such as genes encoding muscle
protein, contractile fiber, myofibril, heart development, muscle
contraction, actin cytoskeleton, actin binding and sarcomere were
significantly enriched (FDR-corrected P,0.05, Figure 2A, Table
S4). A total of 64 genes were found in these GO categories, which
could be further clustered into three groups (muscle protein and
contractile fiber, cytoskeleton protein binding and heart develop-
ment) and the RNA-seq data showed that the majority (54/64)
were up-regulated after Zbed6-silencing. Forty of these genes were
also present in the microarray analysis and half of them were
identified as differentially expressed in both RNA-seq and array
(Figure 2B). These include Tmod1, Homer1, Myoz2, Tpm2, Tnni2,
Actc1, Myom1, Tnnt3 and Casq2, all associated with muscle protein
and contractile fiber, and all were significantly up-regulated after
Zbed6-silencing. Moreover, genes associated with heart develop-
ment (Ttn, Smyd1, Htr2b, Tgfbr1 and Mef2c) were also up-regulated.
For the genes associated with cytoskeleton protein binding, Ndn
and Maea were down-regulated after silencing in both RNA-seq
and array; whereas Dstn, Dync1i1 and Ablim3 were up-regulated
Transcriptional Regulation Mediated by ZBED6
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after silencing. Only one gene (Mtap1b) showed a different
direction of expression changes between RNA-seq and array data
after silencing.
Genes with ZBED6 binding sites are overrepresented
among DE genes after Zbed6-silencing
In our previous C2C12 ChIP-seq experiment [1] we identified
2,500 putative ZBED6 binding sites, with close to 1,200 genes
associated to ZBED6 peaks. Here, we performed a second ChIP-
seq experiment using the Illumina HiSeq system to get a higher
confidence in the localization of ZBED6 binding sites in C2C12
cells. We found a good agreement between the two replicates, but
identified more peaks with better enrichment and resolution in the
new dataset (Figure S3), and thus used the new dataset for
comparison to differential expression. To estimate to what extent
the loss of direct binding of ZBED6 influenced the expression of
the target genes we first compared the new set of ZBED6 peaks
(n = 3,780) to a filtered list of DE genes, where small non-coding
RNAs and genes not present in the refGene dataset were removed.
There was a significant enrichment for ZBED6 binding sites at DE
genes compared to the expressed non-DE genes, and when the
direction of change was considered this difference was found to
come from up-regulated genes (Table 2) suggesting that ZBED6
primarily acts as a repressor.
The RNA-seq analysis at day 2 and 4 showed that there are
three times more DE genes on day 4 than on day 2 but there was
no significant overrepresentation of ZBED6 sites even for up-
regulated DE genes on day 4 (27.2% versus 24.6% for all
expressed genes, P= 0.25). This again suggests that there were
more secondary effects on day 4.
Most of the DE genes were not identified as direct ZBED6
targets, which implies that the majority of differential expression is
caused by secondary effects. We therefore searched the promoter
region (from 22 kb to 2 kb of TSS) of the genes showing
significant up- or down-regulation after Zbed6-silencing for
overrepresentation of other transcription factor binding motifs
using the oPOSSUM software (see Methods). There were five
different motifs significantly overrepresented in up- and down-
regulated genes (Table 3) and all five transcription factors (TFs)
that bind to the corresponding motifs were expressed in C2C12
myoblast cells according to our RNA-seq data. Three of these
transcription factor genes (Nfkb1, Elk4, and Sp1) were only
Figure 1. RNA sequencing of Zbed6-silenced myoblast cells. (A) Quantitative PCR validation of Zbed6-silencing (light gray bar) and Igf2 up-
regulation (dark gray bar) two and four days post-Zbed6 siRNA transfection. Biological triplicates were performed for both Zbed6 and scrambled
siRNA. Error bars, s.e.m. The asterisk indicates a significant difference (P,0.05) between control and Zbed6-silenced samples. (B) Western blot
validation of Zbed6-silencing. The protein lysates from the pooled biological triplicates for each siRNA treatment were equally loaded to the protein
gel after measuring the concentration. The specific band for ZBED6 protein (110 kDa) appeared above the 100-kDa band from the protein ladder and
a-Tubulin was used as a reference protein. (C) Direct comparison of the read counts (y-axis) from Zbed6-silenced and negative control RNA-seq data
across Zbed6 and Igf2 regions for both two and four days post siRNA transfection. The ChIP-seq data with ZBED6 antibody from Markljung et al. [1]
are shown to pinpoint the binding sites of ZBED6.
doi:10.1371/journal.pone.0094187.g001
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overrepresented among down-regulated genes while the other two
(Mef2a and Prrx2) were exclusive to up-regulated genes (Table 3).
Of these genes, only SP1 had a significant ZBED6 ChIP-seq peak,
but Nfkb1 and Elk4 had at least two-fold decrease in expression at
day 2 after Zbed6-silencing according to qPCR analysis (Table 3).
Validation of genes activated by ZBED6
The ZBED6 binding site (59GGCTCGC39) upstream of Igf2 is
100% conserved among all placental mammals with sequence
information. We therefore searched for other conserved matches
to the core motif sequence in close vicinity to ZBED6 peaks
located within 5 kb of genes. Overall, 22% of the peaks had a
conserved GCTCG sequence located within 100 bp of the
summit. For DE genes, we identified 45 genes that were associated
with evolutionary conserved ZBED6 binding sites, with 17 down-
regulated and 28 up-regulated after silencing ZBED6 (Table S5).
There was a higher percentage of conserved sites among down-
regulated genes (39% versus 27% for peaks with a motif match),
however this difference did not reach significance (Fischer’s exact
test, P = 0.12). The up-regulation of Igf2, Ppm1e, Igsf11, Ppm1l,
Ablim3, G3bp2 and Homer1 and the down-regulation of Twist2,
Sfrp2, Socs3 and Slc9a3r1 were confirmed by array data.
Interestingly, motifs in up-regulated ZBED6 target genes were
associated with a palindrome structure that partially overlap the
consensus motif, as is the case at the validated ZBED6 binding site
in Igf2, while none of the down-regulated target genes were
associated with a palindrome (Table S5).
To further explore the effect of the palindrome structure and if
ZBED6 could also function as an activator, we analyzed a
potential binding site 1 kb upstream of Twist2, a gene that encodes
an important basic-helix-loop-helix transcriptional repressor of
muscle-specific genes [11]. Similar to the Igf2 binding site, this
region has a ZBED6 consensus motif overlapping 16-bp that is
highly conserved among all placental mammals (Figure 2C). The
expression of Twist2 was significantly down-regulated after Zbed6-
silencing (Figure 2D), in contrast to the increased Igf2 expression
after Zbed6-silencing. We generated a construct with both the
ZBED6 binding site and promoter from Twist2 and a luciferase
reporter gene cloned into a pGL3 basic vector. We transfected the
construct into either Zbed6-silenced or control C2C12 cells and
measured the luciferase activity; an empty pGL3 basic vector and
a construct with the confirmed ZBED6 binding site from Igf2 were
used as negative and positive controls, respectively. The expression
of the reporter gene after silencing was decreased using the Twist2
construct but increased using the Igf2 construct (Figure 2E),
consistent with reduced Twist2 expression and increased Igf2
expression after Zbed6-silencing.
To confirm that ZBED6 can activate Twist2 transcription, we
used the wild-type Twist2 Luciferase construct (WT) and generated
three different mutant constructs MUT, with a G-to-A mutation,
DEL, with a deletion of the motif, and PAL that has the same
palindrome sequence as present at the Igf2 binding site (Figure 3A).
After transfection of these four constructs into either Zbed6-
silenced or control mouse myoblast cells, the luciferase activities
were measured as before. Compared with the WT construct, both
MUT and DEL reduced the expression of the reporter gene
significantly (Figure 3B). Silencing of ZBED6 resulted in a
significant decrease of the expression for the WT but not for the
MUT and DEL constructs. These results imply that ZBED6
Table 1. Small nucleolar RNA genes significantly up-regulated according to RNA-seq both on day 2 and day 4 after Zbed6 silencing
and qPCR validation.
Gene symbol ZBED6 sites (within 10 kb) Average expression M-value
RNA-seq Day2 RNA-seq Day4 qPCR Day2
Snord12 no high 1.22 1.05 20.10
Snord14c no high 0.87 1.12
Snord14d no high 0.85 0.80
Snord15a no high 1.74 5.13
Snord21 no medium 1.29 1.70
Snord32a yes high 0.64 1.40
Snord34 yes high 0.59 1.22
Snord35a yes high 0.79 0.63
Snord35b no high 1.48 1.02
Snord42a no high 1.32 0.83
Snord47 yes high 1.01 0.89 0.14
Snord49a no high 0.73 1.46
Snord53 no high 1.33 0.56
Snord55 no high 0.98 1.26
Snord57 yes high 1.11 1.31 0.64a
Snord65 no high 1.07 1.73
Snord66 no high 0.86 1.18
Snord82 no high 0.85 1.60 0.59a
Snord95 no high 0.67 1.19 20.28
Snord100 no high 0.67 1.60
aStudent’s t-test, P,0.05).
doi:10.1371/journal.pone.0094187.t001
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Figure 2. Muscle proteins were significantly enriched among the differentially expressed (DE) genes. (A) The significantly enriched GO
categories (y-axis) in the DE genes with FDR ,0.05. (B) The Log2 fold changes from both RNA-seq (dark) and arrays (grey) of the DE genes associated
with muscle proteins and contractile fiber, cytoskeleton protein binding and heart development. (C) The ZBED6 peak at about 1 kb upstream of
Twist2 gene (grey box) displayed together with placental mammal conservation score. The peak maxima overlapped with a highly conserved region
(grey box), which contained the consensus motif GCTCGC of ZBED6 only in the placental mammals. A 10-bp insertion (+10) was present within the
consensus motif in the opossum genome, indicating lack of ZBED6 binding site in this region. (D) The relative expression levels of Twist2 from RNA-
seq and array in either Zbed6-silenced or control C2C12 cells. (E) The relative luciferase activity (the ratio of firefly to Renilla) of Igf2, Twist2 and empty
pGL3 basic constructs in Zbed6-silenced or control C2C12 cells. **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0094187.g002
Transcriptional Regulation Mediated by ZBED6
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e94187
directly binds to the consensus motif upstream of Twist2 and can
activate transcription from the Twist2 promoter, consistent with
the RNA-seq data. Interestingly, the PAL construct that involves
the same palindrome sequence as present at the Igf2 binding site,
showed a significant decrease in reporter gene expression
compared with wild-type (Figure 3B). Furthermore, expression
from the PAL construct increased after Zbed6-silencing (Figure 3B)
implying that ZBED6 acts as a repressor in the context of the
palindrome sequence. To further verify the direct binding of
ZBED6 to the Twist2 upstream region we carried out an
electrophoretic mobility shift assay (EMSA) with wild-type (WT)
and mutant oligonucleotides derived from MUT, DEL and PAL
using nuclear extracts from mouse C2C12 myoblast cells
(Figure 3C). The results indicated specific ZBED6-binding to the
Twist2 WT and PAL sequences but not to the MUT and DEL
sequences in which the GCTCG consensus motif has been
disrupted or deleted. Furthermore, the specificity was supported
by the efficient competition achieved using a 50-fold excess of a
cold Igf2-oligonucleotide containing a validated ZBED6 binding
site. The new ChIP-seq dataset supports binding to Twist2,
however, the signal over this region is relatively weak. To confirm
the in vivo-binding to this region we performed ChIP-qPCR on a
third sample, and further identified enrichment over the corre-
sponding region in ChIP from human cell lines (Figure S4).
ZBED6 binding sites are strongly associated with histone
marks for active promoters
By overlapping the ChIP-seq signal of histone marks from
untreated C2C12 myoblast cells (accession number GSE33227)
with the ZBED6 binding sites, we observed a highly significant co-
localization between ZBED6 and marks associated with open and
active promoters (H3K4me2, H3K4me3 and H3K27ac;
Figure 4A, left panel). No association was seen to marks found
at enhancers (H3K4me1) or throughout expressed genes
(H3K36me3), and further no enrichment was seen for genes
which are in a silent state marked by repressive histone marks such
as H3K27me3 (Figure 4A, left panel). This result was confirmed
by analyzing a previously published dataset [12] on the
distribution of histone marks in C2C12 cells. The average signal
of histone modifications generally decrease over transcription
factor binding sites [13] but for ZBED6 the signal peaked at the
center of the ZBED6 binding sites, suggesting that it does not
require histone-free DNA to bind. We compared the signal for
H3K4me3 centered on the ZBED6 binding sequence GCTCG to
that centered on peaks for a transcription factor (GABPa) known
to bind in the nucleosome-free region upstream of TSS of active
genes [14] and to that of PolII, which show a distribution similar
to ZBED6 (Figure 3A, right panel). We further divided the ZBED6
binding sites into two groups, those associated with genes showing
at least two-fold up-regulation after Zbed6-silencing and those at
least two-fold down-regulated; only genes containing ZBED6 sites
within 5 kb up- or downstream of TSS were included here. We
observed similar profiles in the two groups for all six histone
modifications except H3K4me2 (Figure S5). There was a stronger
enrichment of the active histone mark H3K4me2 modification in
the vicinity of ZBED6 binding sites of down-regulated genes after
Zbed6-silencing (P,0.001, Student’s t-test) compared with up-
regulated genes.
Table 2. Analysis of the correlation between differential gene expression (DE) after Zbed6 silencing and the presence of ZBED6
binding sites within 5 kb of the transcription start site (TSS).
DE genes
ZBED6 sites Non DE genes All Up-regulated Down-regulated
Yes 2681 (24.6%) 187 (29.8%)a 131 (32.8%)a 56 (24.6%)
No 8194 440 268 172
Total 10875 627 399 228
aOverrepresentation of genes with ZBED6 binding sites among DE genes (Chi square test, two-tailed, d.f. = 1; Non DE genes vs All DE genes, P = 0.004; Non DE genes vs
up-regulated DE genes, P = 0.002)
doi:10.1371/journal.pone.0094187.t002
Table 3. Overrepresentation analysis of transcription factor binding sites within 2 kb up- or downstream of the transcription start
site of genes showing significant differential expression after Zbed6-silencing in C2C12 myoblast cells.
Transcription TF Up-/Down- regulation Enrichment Expression analysis
factor class na Pb Mc Pd
NFKB1 REL down 125 1.54E-04 22.03 0.01
ELK4 ETS down 180 3.99E-04 21.15 0.01
SP1 C2H2 down 318 3.24E-02 20.21 0.54
MEF2A MADS up 98 1.27E-10 20.58 0.22
PRXX2 HOMEO up 186 4.72E-08 0.52 0.23
aNumber of genes containing the transcription factor binding site.
bFisher’s exact test.
cM-values represent log2 transformation of fold changes between Zbed6-silenced samples and negative controls estimated by qPCR analysis. Triplicates for each
treatment were used.
dStudent’s t-test were used to calculate the statistical significance.
doi:10.1371/journal.pone.0094187.t003
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Histone modifications are differentially enriched at genes
encoding muscle proteins after Zbed6 silencing
To investigate whether silencing of ZBED6 causes a change in
the histone marks, we performed ChIP sequencing on silenced and
control cells with antibodies for the histone marks H3K4me3,
H3K36me3, H3K4me2, and H3K9ac on day 4 after treatment
(accession number SRA058767). The signal footprints over all
TSS in the genome showed the expected pattern with a major
peak downstream of TSS and an overall similar enrichment in
silenced and control cells for the different modifications (Figure 4B,
left panel). The combined ZBED6 signal has the maximum close
to that for the active marks, 120 bp downstream of TSS. Zbed6-
Figure 3. Luciferase assays for the Twist2 locus using constructs
where the ZBED6 binding site was altered. (A) The 24-bp
conserved ZBED6 binding site at the Twist2 gene (WT) was mutated
to generate MUT containing a single G-to-A mutation at the ZBED6
consensus motif, to DEL by deleting the consensus motif, and to PAL by
altering two nucleotides that created the same palindrome sequence as
present at the Igf2 locus (PAL). (B) The relative luciferase activity (the
ratio of firefly to Renilla) of WT, MUT, DEL, PAL constructs in Zbed6-
silenced (blue) or control C2C12 cells (pink). Standard errors of the
mean are displayed by the error bars. ***, P,0.001. (C) EMSA of WT,
MUT, DEL, PAL and Igf2 biotin probes incubated with C2C12 nuclear
extracts showing binding of endogenous ZBED6 to the WT, PAL and
Igf2 biotin probes but not to the MUT and DEL biotin-probes. The
binding complex was competed using an 100-fold excess of the
corresponding Twist2 cold probe or Igf2 cold probe.
doi:10.1371/journal.pone.0094187.g003
Figure 4. Histone modifications associated with ZBED6 target
sites and other sites in C2C12 myoblast cells. (A) Left panel: ChIP
sequencing data from six histone modifications including H3K4me2
(dark red), H3K4me3 (green), H3K27ac (purple), H3K4me1 (dark blue),
H3K27me3 (pink), and H3K36me3 (black) located within 1 kb from
ZBED6 target sites (white square). Right panel: enrichment of H3K4me3
over GABPa (grey), ZBED6 (dark) and Polymerase II (Pol-II) binding sites
(light blue). (B) Left panel: genome-wide enrichment over TSS for active
histone marks including H3k4me2 (dark red), H3K4me3 (green), H3K9ac
(dark blue) in silenced (narrow lines) and control cells (bold lines).
Signals for ZBED6 (dark) are shown for reference. Right panel: ratio of
the enrichment between silenced and control (silenced/control) over
ZBED6 peak centers for H3K4me2 (dark red), H3K4me3 (green) and
H3K9ac (dark blue). (C) The histone modification ratios between
silenced and control samples downstream of TSS for up-regulated
and down-regulated (blue) genes after Zbed6 silencing normalized to
counts for all non-DE genes.
doi:10.1371/journal.pone.0094187.g004
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silencing had no major impact on the K4me2, K4me3 and K9ac
signals over the ZBED6 binding sites as indicated by the silenced/
control ratio for these histone marks (Figure 4B, right panel). We
further analyzed the silenced/control ratios of K4me2, K4me3,
K36me3 and K9ac reads in the first 2 kb downstream of TSS of
all DE genes divided into up- and down-regulated genes. We
observed a significantly higher enrichment for all modifications at
up-regulated genes (Figure 4C), which further validates the RNA-
seq results. Even though the DE genes had a significant change in
the histone modification pattern as a group, many individual genes
did not show any difference. We used the nine muscle related
genes from the significant GO categories described above (Tmod1,
Homer1, Myoz2, Tpm2, Tnni2, Actc1, Myom1, Tnnt3 and Casq2),
which were identified as DE both by arrays and RNA-seq, as a set
of true positive up-regulated genes and calculated the fold changes
for these. The average fold changes for these genes were higher
than the average for all up-regulated genes. H3k9ac showed the
largest changes, with all nine genes above the average (median fold
change = 1.33).
To test if the histone modification changes after Zbed6 silencing
supports the GO findings from the RNA-seq analysis categories,
the 300 genes with the highest fold changes for H3K9ac was
analyzed in the same way as DE genes using the DAVID software,
with the genes expressed in C2C12 cells as the background. This
gave highly significant enrichments for the same muscle-related
categories as described above, with 17 of the 300 genes annotated
as myofibril and contractile fibre (Table S6).
In conclusion, the data on histone marks suggest that ZBED6
interacts with active promoters and modulate their activity without
recruiting major repressive histone modifications, and that the
effect of Zbed6 silencing is reflected in the histone modification
pattern in agreement with the RNA-seq results.
ZBED6 modulates the expression of Igf2 and Myogenin
during differentiation of C2C12 cells
C2C12 cells are differentiated towards myotubes when grown in
low serum media. Myogenin (MYOG) is a muscle-specific
transcription factor that is essential for myogenesis and shows
together with IGF2 strongly induced expression during differen-
tiation of C2C12 cells. We decided to explore how perturbed
expression of ZBED6 affects Igf2 and Myogenin expression during
differentiation. Differentiation of C2C12 led to a minor (30–40%)
increase in ZBED6 expression (Figure 5). Igf2 and Myog showed
very low levels of expression in undifferentiated C2C12 but
differentiation led to a dramatic increase in their expression
(Figure 5A and 5B). Overexpression of ZBED6 resulted in a
significantly reduced expression of Igf2 and Myog both in
differentiated and undifferentiated C2C12 cells (Figure 5A), with
almost halved expression at day 2.5. Consistent with this result,
ZBED6 silencing resulted in increased expression of Igf2 and
Myogenin but this two-fold change was small compared with the
dramatic change induced by differentiation (Figure 5B). The
results demonstrate that ZBED6 does not determine if Igf2 and
Myogenin expression is on or off, but it modulates their level of
expression after a developmental program has activated them.
Discussion
The present study demonstrates that ZBED6 is an important
transcriptional modulator since Zbed6-silencing in mouse C2C12
cells combined with transcriptome analysis revealed consistent
changes in expression levels for more than 700 genes. Many of
these transcriptional changes are likely to be secondary effects but
the finding of a significant enrichment of differentially expressed
genes associated with one or more ZBED6 binding sites,
particularly for genes that are upregulated after ZBED6 silencing,
strongly suggests that ZBED6 has many functional target sites in
the genome besides the well-established and evolutionary
conserved site in the third intron of IGF2. The finding of a fairly
high proportion of differentially expressed genes lacking ZBED6
binding sites, implying that they represent secondary effects, was
not unexpected since other transcription factor genes are highly
enriched among the putative ZBED6 targets established by ChIP-
seq analysis [1].
RNA-seq-based fold changes between Zbed6-silenced and
control cells were significantly correlated with the fold changes
measured by microarray hybridizations (r = 0.30, P,0.001) and
the strength of correlation was similar to that observed in previous
RNA-seq studies [15]. However, the correlation between the two
platforms was weaker than the correlation between RNA-seq-
derived fold changes from day 2 and day 4. One possible
explanation for this is that we used a poly-A enrichment procedure
for the RNA-seq experiment but not for the array experiment.
Among the 780 DE genes identified by RNA-seq, we found a
better correlation between RNA-seq and array data (r = 0.56, P,
0.001) and at least one third of the genes that were identified as
expressed in the array were validated as DE genes with the array.
Especially for genes enriched in the top three Gene Ontology
classifications (muscle protein and contractile fiber, heart devel-
opment, and cytoskeleton protein binding, Figure 2B), all twenty
genes except one had the same direction of fold changes between
the two platforms, changes that all were statistically significant.
The correlation between qPCR and RNA-seq fold changes of a
small subset of genes was highly significant (r = 0.86, P,0.001) and
eight out of twelve genes that were tested showed statistical
significance using both methods. The excellent correlation
observed for the 780 DE genes when comparing RNA-seq and
microarray data across a large set of genes combined with qPCR
data for a small set of genes confirm that our RNA-seq
experimental design has generated reliable data for inferring
differential gene expression between Zbed6-silenced cells versus
untreated control cells.
The genes showing differential expression after Zbed6-silencing
were significantly enriched for the GO terms muscle protein and
contractile fibers (Table S4). The up-regulated genes encoding
tropomodulin 1 (Tmod1), homer homolog 1 (Homer1), myozenin 2
(Myoz2), topomyosin 2 (Tpm2), skeletal troponins (Tnni2 and
Tnnt3), actin alpha cardiac muscle 1, myomesin 1 (Mymo1), and
calsequestrin 1 (Casq1) constitute the majority of the contractile
fiber category. These results are consistent with our previous
observation that Zbed6-silencing resulted in increased myotube
formation [1], because myotube formation requires the imple-
mentation of the contractile properties necessary for mature
muscle fiber function [16]. However, only one of these nine genes,
Homer1 contains ZBED6 binding sites within 5 kb of TSS,
indicating that the regulation of contractile fiber genes by ZBED6
is not direct but rather secondary effects on transcription probably
regulated through other growth factors or transcription factors
directly targeted by ZBED6. In agreement with this notion is that
one growth factor (Igf2) and two myogenic transcription factors,
myocyte enhancer factor 2c (Mef2c) and twist homolog 2 (Twist2),
were differentially expressed after Zbed6-silencing. IGF2, an
embryonic regulator of myogenesis and an autocrine factor that
induces myoblast differentiation in vitro [17], is repressed by
ZBED6 through a 59GCTCG39 consensus site. Mef2c is a well-
known co-regulator for myogenesis [18] and it can activate the
expression of downstream targets including muscle contraction
genes [19]. Mef2c showed significantly greater expression after
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Zbed6-silencing, but there were no ZBED6 sites associated with
this gene, thus the repression may not be through direct
regulation. Twist2, which is known for its ability to inhibit
myogenesis by repressing the transactivation activity of Myod1 and
Mef2c [11], was suppressed by the silencing of ZBED6 and
contains an evolutionarily conserved ZBED6 binding site located
immediately upstream of its TSS. Our Luciferase reporter assays
and electrophoretic mobility shift assay suggested that Twist2 may
be a ZBED6 target. Therefore, ZBED6 may inhibit myogenesis
through directly repressing Igf2 and promoting Twist2 expression.
A striking observation in the present study was the differential
expression of genes encoding small nucleolar RNAs (snoRNAs).
We found that the expression levels of 20 mouse snoRNAs
identified by RNA-seq were significantly increased after Zbed6-
silencing on both days. Two out of the five randomly selected
snoRNAs were confirmed to be differentially expressed by qPCR
Figure 5. ZBED6 modulates the expression of Igf2 and Myogenin during differentiation of C2C12 cells. (A) Expression of ZBED6, IGF2
and Myogenin mRNA monitored by qPCR before and after differentiation of control cells and transfected cells overexpressing ZBED6 from the pTRE-
ZB vector. (B) Expression of ZBED6, IGF2 and Myogenin mRNA monitored by qPCR before and after differentiation of control cells and cells in which
ZBED6 has been silenced using siRNA. (C) Western blot analysis confirming altered expression of ZBED6 and Myogenin at the protein level. Actin was
used as loading control.
doi:10.1371/journal.pone.0094187.g005
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validation. Interestingly, five out of the twenty snoRNAs contained
ZBED6 binding sites within 10 kb of the TSS (Table 1). This
indicates that ZBED6 directly or indirectly represses the
transcription of these snoRNAs, which play important roles in
pre-rRNA processing and modification in the nucleolus [20]. We
previously showed that ZBED6 has both a nuclear and nucleolar
localization sequence but has more intensive staining in the
nucleolus versus nucleoplasma [1]. The functional significance of
the nucleolar localization is not yet understood. Here we have
discovered a potential role of Zbed6 in regulation of snoRNAs
expression in the nucleolus.
Does ZBED6 always act as a repressor? ZBED6 functions as a
repressor of Igf2 in vivo by binding to a highly conserved sequence
in the IGF2 locus [1,2]. Here, we found an enrichment for ZBED6
peaks at up-regulated genes which indicates that it is mainly a
repressor. However, many down-regulated genes were associated
to evolutionary conserved ZBED6 binding sites. A luciferase
reporter assay supported the interpretation that Twist2, one of
these down-regulated ZBED6 targets, is activated by ZBED6
through binding to its evolutionary conserved ZBED6 site. We
found that a palindrome structure partially overlapping with the
ZBED6 consensus motif was only associated with genes that were
up-regulated after silencing suggesting that ZBED6 acts as a
repressor at those sites. A previous study showed that mutations
disrupting the palindrome structure at the Igf2 QTN locus
increased transcription of the reporter gene but did not affect
ZBED6 binding [21]. Our EMSA and luciferase data (Figure 3)
also showed that the palindrome structure that were created at the
Twist2 locus did not affect ZBED6 binding but switched the
transcriptional activation to repression of the reporter gene. Thus,
ZBED6 may act as a repressor if it binds to the consensus motif
associated with a palindrome structure, while it may act as an
activator in the absence of a palindrome. Furthermore, our
previous in vitro DNA binding experiments showed that ZBED6
binding is sensitive to CpG methylation and only binds to non-
methylated DNA [2]. The resulting chromatin structure obtained
from CpG methylation and histone modifications, the presence or
absence of the palindromic sequence and the functional interac-
tions with other transcription factors that need to be present
together with ZBED6 may determine whether ZBED6 can access
a site and whether it acts as a transcriptional repressor or activator.
Our results reveal an emerging picture that ZBED6 tends to
bind active promoters where it acts as a modulator of transcription
rather than as a classical repressor or activator that acts via
recruiting histone modifications. First, we found that ZBED6 sites
are associated with high levels of H3K4me3, H3K4me2 and
H3K27ac modifications, which are usually found at active
promoters [22–24]. There was no enrichment of the repressive
histone mark H3K27me3 at ZBED6 sites, which is consistent with
our previous finding that ChIP-PCR did not reveal any change in
the level of H3K27me3 modification at the Igf2 locus after Zbed6-
silencing [1]. Interestingly, a similar somewhat surprising associ-
ation with active chromatin was recently detected for the SMRT
corepressor [25]. Furthermore, our results when comparing
undifferentiated and differentiated C2C12 cells (Figure 5) suggest
that ZBED6 does not determine whether a gene is on or off but
affects the level of expression after a developmental program has
activated gene expression. This interpretation is fully consistent
with the established role for ZBED6 in regulating IGF2 expression
in pig skeletal muscle. IGF2 is expressed in wild-type pigs, which
means that the promoter must be active, but IGF2 is three-fold
upregulated in mutant pigs, in which the ZBED6 binding site in
IGF2 intron 3 has been disrupted [2].
Materials and Methods
Cell culture
The C2C12 cells (ATCC, CRL-1772) used for these studies
were between passages 10 and 18. Cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) with L-glutamine
(ATCC, 30-2002), supplemented with 10% heat-inactivated fetal
bovine serum and penicillin (0.2 U/mL)/streptomycin (0.2 mg/
ml)/L-glutamine (0.2 mg/ml) (Gibco) at 37uC in a 5% CO2
humidified atmosphere. For the transfection experiments, cells
were trypsinized at 70–80% confluence, and seeded at 100,000
cells per well in 12-well plates (Falcon).
Differentiation of C2C12
Differentiation of C2C12 cells was induced by replacing the
growth medium with a differentiation medium containing 2%
horse serum. Total RNA and protein were extracted from the cells
at the desired time point.
Gene silencing using siRNA and validation
Cells were seeded in complete DMEM lacking antibiotics and
reverse transfected with siRNA by lipofectamine 2000 (Invitrogen).
Zbed6-silencing experiment and the validation of silencing with
quantitative PCR and Western blotting followed the previous
description [1]. Briefly, C2C12 cells were treated with Zbed6
siRNA or scrambled siRNAs for two or four days in biological
triplicates. Total RNA from each sample was extracted for qRT-
PCR validation and microarray analysis. For qPCR validation,
both 18S rRNA and beta-actin were used as endogenous controls.
RNA-seq analysis used the pooled mRNA from the triplicates for
each siRNA treatment. The protein lysates before and after two
days Zbed6-silencing were prepared for western with anti-ZBED6
antibody and the a-Tubulin antibody (Cell signaling, #2144) as a
reference.
The primer and probe sets for all qPCR reactions are listed in
Table S7. All probes were TaqMan MGB probes with 59-6FAM
labels and 39-non-fluorescent quenchers (Applied Biosystems). The
qPCR validation of differentially expressed genes was done with
the SYBR Green master mix (Applied Biosystems) according to
the manufacturer’s protocol. The fold-change expression was
calculated by using the 22DDCT method and Student’s t-test was
used to calculate the statistical significance.
The western and qPCR validation of the Zbed6 silencing used
for RNA-seq and array analysis were all based on the same siRNA
experiment. The qPCR validation of differentially expressed genes
identified by RNA-seq and all luciferase reporter assays were
performed with new siRNA experiments.
RNA sequencing analysis
Total RNA from C2C12 cells treated with scrambled siRNAs or
Zbed6 siRNAs two or four days post-transfection was isolated using
the RNeasy mini kit (Qiagen). RNA triplicates from each
treatment were pooled equally for mRNA enrichment by using
the MicroPoly (A) Purist kit (Ambion). The quality and quantity of
the mRNA was evaluated with a BioAnalyzer 2100 (Agilent).
About 1 mg mRNA for each sample was used for RNA sequencing
by AB SOLiD system (Life technologies). The fragment library
was constructed according to the manufacturer’s protocol (SOLiD
Whole Transcriptome Analysis). Sequencing for each sample was
done on a quarter of a slide and gave about 50 million 50 bp reads
each. Wiggle files with read counts for genes were exported for
UCSC browser to visualize the data. Ensembl gene model was
modified to combine alternative transcripts into one gene. With
the modified Ensembl gene model, we calculated gene expression
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by the reads per kilobase of gene model per million mapped reads
(RPKM).
Microarray analysis
All RNA samples used in array analyses had excellent quality
according to Bioanalyzer. Biotinylated probes were prepared from
250 ng of total RNA, using the Ambion Illumina TotalPrep RNA
Amplification kit (Applied Biosystems). The complete set of RNA
was hybridized to MouseRef-8_v2 BeadChips (25K, Illumina).
The raw data were processed using the software FlexArray
(Version 1.4.1) [26,27], which invokes R. The ‘‘lumi’’ algorithm
bundle was chosen for data normalization.
Significant differential gene expression
DEGseq [10] was used to identify differentially expressed genes
from RNA-seq data, with random sampling model based on the
reads count of each gene from Zbed6-silenced cells versus control
cells. Statistical difference in gene expression for RNA-seq data
was evaluated by the MA-plot-based method with random
sampling model. M-values were determined by taking the log2
ratio of counts for silenced samples to that for controls. A-values
were determined by taking the average log2 counts for silenced
samples and controls. It was proven that under the random
sampling assumption the conditional distribution of M-value given
an observation of A-value follows an approximate normal
distribution. The P-value was assigned based on the conditional
normal distribution. Significant differential gene expression was
determined using the following criteria: (i) less than 0.1% FDR, (ii)
the same direction of fold change between day 2 and day 4, and
(iii) at least 1.5 fold changes.
For the microarray data, statistical significance was evaluated
using Bayes t-tests where three biological replicates of each
treatment were contrasted against the opposite treatment at the
same time point (the RNA-seq data was originated from an equal
pooling of these triplicates). The P-values were corrected for
multiple testing by using the Benjamini Hochberg approach [28].
The microarray criterion for DE was P,0.05 and the same
direction of fold change between day 2 and day 4.
Correlation analysis
For RNA-seq, microarray and qPCR analysis, the fold-change
expression levels were calculated by the methods described in
previous sections. The fold-change values were correlated and
compared between platforms by using Pearson’s correlation
coefficient (r). The t-test was used to establish if the correlation
coefficient is significantly different from zero.
Gene Ontology analysis
The Ensembl Gene IDs of genes were submitted to the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.
gov/) for the functional annotation chart analysis. The default
setting was used for the GO analysis. We used the criteria of FDR-
corrected P,0.05 and fold enrichment .2.5 to identify the
significantly enriched GO categories.
Overrepresentation of conserved transcription factor
binding sites
To identify conserved ZBED6 binding sites, we use phast-
Cons30wayPlacental scores of UCSC Genome Browser to
measure conservation base by base. All ZBED6 peaks with a
peak height of at least 12 were scanned for the presence of
GTCTG sequences within 100 bp of the summit and the average
conservation score was computed for each motif. The ZBED6
motif was considered conserved if the average conservation score
was larger than 0.90.
To discover over-represented conserved transcription factor
binding sites at the TSS of DE genes we used the web-based
version 2.0 of oPOSSUM [29,30]. Both up-regulated and down-
regulated genes after Zbed6-silencing whether containing ZBED6
binding site or not were submitted for the module of Single Site
Analysis. The software uses phylogenetic footprinting to reveal
overrepresented matrices from the Jaspar database in foreground
sequences. Statistical significance of results is measured by Fisher-
score and Z-score and the significance criteria of Z-score .10 and
Fisher score ,0.05 were applied based on empirical studies. The
Ensembl gene IDs for mouse were uploaded and scanned from 2
2 kb to +2 kb of the TSS against Jaspar vertebrate core profile.
Level of conservation and matrix match threshold were kept at
maximum. The over-represented transcription factors were sorted
on bases of Fisher-score and overlapped with our RNA-seq data to
filter out the factors that were not expressed in the C2C12
myoblast cells.
DNA constructs for transfections
DNA constructs for the IGF2 QTN were previously described
[1]. Briefly, luciferase reporter plasmids contained 272 bp of the
porcine IGF2 P3 promoter, either alone or with either the wild
type IGF2 QTN region or mutant QTN region (581 bp insert)
cloned directly upstream of the promoter. The difference between
the wild type and mutant QTN is the substitution of an A for G at
position 212 in the mutant construct. The Twist2 pGL3 construct
contained an 825 bp insert (chr1: 93697292-93698116, Mouse
July 2007 (NCBI37/mm9) assembly) with two putative ZBED6
binding sites (starting pos. 936973472 strand and 93697464+
strand) and the Twist2 promoter region cloned into the pGL3 basic
vector (Promega). Constructs with the single mutation at the
consensus motif (MUT), the deletion of the motif (DEL) and the
creation of the palindrome sequence (PAL) in Figure 3 were
generated with the QuickChange Site-Directed Mutagenesis kit
according to the manufacturer’s instructions (Agilent Technolo-
gies). In short, the mutations were made with ancestral Twist2-
pGL3 construct as a template, and with oligonucleotides lacking
the consensus motif or with point mutation(s). A synthetic vector
was generated from the oligonucleotides annealed to the Twist2-
pGL3 vector with Pfu Turbo polymerase (Agilent Technologies),
and the ancestral vector was then digested with DpnI. The mutated
constructs were sequenced to confirm the mutations. All DNA
constructs were prepared by using EndoFree Plasmid Maxi kit
(Qiagen).
DNA transfections and reporter gene activity assays
After 24–48 h of incubation with siRNA treatments, C2C12
cells were washed and covered with Opti-MEM I Reduced Serum
Media (Invitrogen). Cells were co-transfected with 1 mg of one
endo-free DNA construct described in previous sections and 20 ng
of Renilla vector, ph-RG-TK (Promega), using Opti-MEM I
Reduced Serum Media and lipofectamine 2000 CD (Invitrogen).
Cells were incubated for 24 h and luciferase activity was measured
using the Dual Luciferase Reporter Assay Kit (Promega) and an
Infinite M200 Luminometer (Tecan). Activity was expressed as
relative luciferase units, the ratio of firefly luciferase activity to
Renilla luciferase activity. Triplicates within an experiment were
averaged. The experimental unit was defined as the experiment,
with N=4 experiments. Relative luciferase units were transformed
(logX +1) to reduce heterogeneity of variance. Transformed data
were analyzed in SigmaPlot v. 11.0 (Systat Software, Inc.) by two-
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way ANOVA. The statistical model included the main effects of
siRNA treatment and DNA construct and the two-way interac-
tion. Differences were considered significant at P,0.05. The
Holm-Sidak method was used as a post-hoc test to evaluate all
pairwise comparisons. Non-transformed data are shown graphi-
cally.
Electrophoretic mobility shift assay (EMSA)
The ZBED6 binding sites in pig IGF2 intron 3 and upstream
mouse Twist2 were used as probes to detect sequence-specific
ZBED6 binding in vitro. The probes used were as follows: IGF2
wt, 59-CTTCGCCTAGGCTCGCAGCGCGGGAGCGA-39;
Twist2 wt, 59-TGGGCGCTCCCGCAGAGGCTCGCTGT-
GATGCCTAAGCT-39; Twist2 mut, 59-TGGGCGCTC-
CCGCAGAGGCTCACTGTGATGCCTAAGCT-39; Twist2
pal, 59- TGGGCGCTCCCGCCTAGGCTCGCTGTGATGC-
CTAAGCT-39; and Twist 2 del, 59- TGGGCGCTCCCGCA-
GAGCTGTGATGCCTAAGCT-39. ZBED6 binding sites are
underlined, and altered sites are indicated in bold (Figure 3A). The
probes were purchased 59-Biotin labelled from Integrated DNA
Technologies (Leuven, Belgium). Single-stranded complementary
oligos were annealed in 1X NEB2 buffer (New England Biolabs) at
2 min at each degree from 95uC to 25uC to produce double-
stranded probes. The binding reactions were then performed as
previously described [1], with minor modifications. Briefly, a total
of 3 mg C2C12 nuclear extracts was preincubated on ice for
20 min in binding buffer (kit specific binding buffer with
supplements: 30.1 mM KCl, 2 mM MgCl2, 0.1 mM EDTA,
0.063% NP-40, 7.5% Glycerol, 1 mg/ml Poly(dINdC)). Competi-
tion reactions were supplemented with 20 pmol (100-fold molar
excess) unlabeled ds-oligonucleotide. After the addition of
200 fmol 59-Biotin labeled ds-oligonucleotide, reactions were
incubated at RT for 30 min. The protein–DNA complexes were
separated on a 5% polyacrylamide gel (BioRad) run in 0.56TBE
at 100 V for 2:30 h in RT. Transfer to nylon membranes (Perkin
Elmer) was carried out in 0.56TBE at 45 V, 4uC for 1 h. The
DNA was crosslinked for 15 min on a transilluminator with
312 nm bulbs, and then detected by the Lightshift Electropho-
retic Mobility-Shift Assay kit (Thermo Scientific) by using
streptavidin-horseradish peroxidase binding and chemilumines-
cent detection.
ChIP-seq and histone modification analysis
Chromatin immunoprecipitation was done as previously
described [1]. Briefly, C2C12 cells with and without Zbed6 siRNA
treatment were crosslinked using 1% formaldehyde for 10 min.
Cells were lysed with cell lysis buffer and nuclei were resuspended
in RIPA buffer and sonicated using a BioRuptor (Diagenode) to
shear the chromatin. Antibodies for H3K4me3 (Millipore
cs200554), H3K9Ac (Abcam ab4441) and H3k4me2 (Millipore
07-030) were bound to Protein-G magnetic beads (Invitrogen) and
incubated with chromatin from 5-10 M cells per reaction at +4uC
degrees for several hours. Beads were washed with RIPA and LiCl
buffers and chromatin was eluted with SDS buffer. Indexed
Illumina libraries were made using NEXTflex adaptors (BIOO
Scientific) and sequenced to 50 bp on a HiSeq2000 instrument.
Ampure XP (Beckman Coulter) was used to purify both eluted
chromatin and the library reactions. The ZBED6 ChIP-seq
experiment was done independently from the silencing experi-
ment, with a higher cell count.
Reads were aligned to the mouse mm9 assembly using BWA
with default parameters, and MACS [31] was used to identify
peaks and create wiggle files with the signals. For histone
modification enrichment analysis, BEDTools coverageBed [32]
was used to count the number of uniquely aligned reads (mapping
quality above 10) in a 2-kb window downstream of TSS. Only
genes present in the refGene table (downloaded from the UCSC
genome browser) was used. For genes with multiple TSS, only the
TSS with the highest read count for H3K4me3 in the control
sample was used for the analysis. The Mann-Whitney test was
used to calculate significance of count differences.
ChIP-seq datasets for GABPa and PolII were downloaded from
the ENCODE repository through the UCSC genome browser.
Histone modification analysis over ZBED6 target sites
ChIP-sequencing reads for six histone modifications in C2C12
myoblast cells including H3K4me1, H3K4me2, H3K4me3,
H3K27me3, H3K27ac and H3K36me3 were aligned to the
Mouse genome July 2007 (NCBI37/mm9) assembly by using
Mosaik (version 1.0.1384) with default parameters (http://
bioinformatics.bc.edu/marthlab/Mosaik). The uniquely aligned
reads were submitted for calling peaks by using Model-based
analysis of ChIP-sequencing (MACS). We extracted the signals for
each histone mark in a 3.5 kb window surrounding the center of
the ZBED6 peak maxima and made the plot with the average
overlapped reads for all six histone modifications. We did similar
plots for both up- and down-regulated ZBED6 target genes after
the silencing.
Overexpression of ZBED6
The coding sequence of mouse ZBED6 was cloned directly
downstream of Tetracycline-responsive promoter in pTRE-
Tight vector (Clontech) between BamHI and SalI sites. The
EndoFree Plasmid Maxi kit (Qiagen) was used to produce
endotoxin-free pTRE-ZB construct. In the same time, Tet-On-
Advanced vector (Clontech) was used to generate stable
C2C12 cell line expressing Tet-controlled transactivator
protein. Those stable cells were transit transfected with
pTRE-ZB construct (1 mg/ml) using lipofectamin2000 (Invi-
trogen). Doxycycline (500 ng/ml) was added to the culture
medium to induce the expression of ZBED6 from pTRE-ZB
vector.
Immunoblot analysis
Cells were washed with PBS and lysed in RIPA lysis buffer
containing protease inhibitors (Roche). Lysates were vortexed and
incubated on ice for 15 min and centrifuged at 13000 RPM for
15 min at 4uC. The supernatants were transferred into new tubes
and the concentrations of the proteins were determined by
Bradford protein assay (BioRad). Equal amounts of total lysates
were separated by SDS-PAGE gels (4%–12%, Bio-Rad) and
transferred into PVDF membranes (Millipore). Membrane was
blocked by SuperBlock blocking buffer (Thermo scientific) and
then incubated overnight at 4uC with diluted primary ZBED6
(1:1000), Myogenin (1:1000, SantaCruz) or Actin (1:5000, Abcam)
antibodies. Thereafter, the membrane was incubated with
secondary anti-rabbit IgG or anti-mouse IgG (1:5000, cell
signaling) antibodies conjugated to horseradish-peroxidase
(HRP). Proteins were visualized and detected by chemilumines-
cence ECL prime detection reagent (Amersham).
Data access
The RNA-seq data from this study have been submitted to the
NCBI Sequence Read Archive (http://trace.ncbi.nlm.nih.gov/
Traces/sra/) under accession number SRA047361. The micro-
array data and the ChIP-sequencing data have been submitted to
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NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE33430 and GSE33227.
Supporting Information
Figure S1 The distribution of the mRNA expression of
the Ensembl genes measured by RPKM (reads per
kilobase of gene model per million mapped reads).
(PDF)
Figure S2 Analysis of RNA-seq data. A. The correlation
between the Log2 RNA-seq fold changes computed on the data
from day 4 (y-axis) versus that from day 2 (x-axis); B. The
correlation between the Log2 fold changes measured by RNA-seq
and microarrays for all genes.
(PDF)
Figure S3 Results of ZBED6 ChIP-seq analysis in C2C12
cells.
(PDF)
Figure S4 Validation of ZBED6 binding to the conserved
element upstream of Twist2.
(PDF)
Figure S5 Enrichment analysis of six histone modifica-
tions across ZBED6 target sites. ZBED6 target genes were
divided into up-regulated and down-regulated genes after Zbed6
silencing.
(PDF)
Table S1 Summary of RNA sequencing and reads
mapping.
(PDF)
Table S2 Differentially expressed genes identified by
RNA-seq.
(PDF)
Table S3 qPCR validation of 12 differentially expressed
genes that were identified by RNA-seq.
(PDF)
Table S4 Gene Ontology analysis of genes with differ-
ential expressions identified by RNA-seq.
(PDF)
Table S5 Twenty-six differentially expressed genes with
evolutionary conserved ZBED6 binding sites.
(PDF)
Table S6 Significant GO categories for the top 300
H3K9ac genes.
(PDF)
Table S7 Primer and probe sets for qPCR validation.
(PDF)
Acknowledgments
Thanks are due to the Uppsala Genome Center for SOLiD sequencing and
UPPMAX for help with data storage and analysis. We thank the McGill
University Genome Quebec Innovation Centre for performing the
Illumina BeadChip hybridization experiments.
Author Contributions
Conceived and designed the experiments: LJ OW SY CJR ES TSM GA
LA. Performed the experiments: LJ OW SY CJR ERG ES AG XZ LW.
Analyzed the data: LJ OW SY CJR ES AG XZ LW TSM GA LA. Wrote
the paper: LJ OW SY CJR GA LA.
References
1. Markljung E, Jiang L, Jaffe JD, Mikkelsen TS, Wallerman O, et al. (2009)
ZBED6, a novel transcription factor derived from a domesticated DNA
transposon regulates IGF2 expression and muscle growth. PLoS Biol 7:
e1000256.
2. Van Laere AS, Nguyen M, Braunschweig M, Nezer C, Collette C, et al. (2003)
A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in
the pig. Nature 425: 832–836.
3. Aravind L (2000) The BED finger, a novel DNA-binding domain in chromatin-
boundary-element-binding proteins and transposases. Trends Biochem Sci 25:
421–423.
4. Calvi BR, Hong TJ, Findley SD, Gelbart WM (1991) Evidence for a common
evolutionary origin of inverted repeat transposons in Drosophila and plants:
hobo, Activator, and Tam3. Cell 66: 465–471.
5. Andersson L, Andersson G, Hjalm G, Jiang L, Lindblad-Toh K, et al. (2010)
ZBED6: The birth of a new transcription factor in the common ancestor of
placental mammals. Transcr 1: 144–148.
6. Boisvert FM, van Koningsbruggen S, Navascues J, Lamond AI (2007) The
multifunctional nucleolus. Nat Rev Mol Cell Biol 8: 574–585.
7. Ali SA, Zaidi SK, Dacwag CS, Salma N, Young DW, et al. (2008) Phenotypic
transcription factors epigenetically mediate cell growth control. Proc Natl Acad
Sci U S A 105: 6632–6637.
8. Butter F, Kappei D, Buchholz F, Vermeulen M, Mann M (2010) A domesticated
transposon mediates the effects of a single-nucleotide polymorphism responsible
for enhanced muscle growth. EMBO Rep 11: 305–311.
9. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and
quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621–628.
10. Wang L, Feng Z, Wang X, Zhang X (2010) DEGseq: an R package for
identifying differentially expressed genes from RNA-seq data. Bioinformatics 26:
136–138.
11. Gong XQ, Li L (2002) Dermo-1, a multifunctional basic helix-loop-helix
protein, represses MyoD transactivation via the HLH domain, MEF2
interaction, and chromatin deacetylation. J Biol Chem 277: 12310–12317.
12. Asp P, Blum R, Vethantham V, Parisi F, Micsinai M, et al. (2011) Genome-wide
remodeling of the epigenetic landscape during myogenic differentiation. Proc
Natl Acad Sci U S A 108: E149–158.
13. Kundaje A, Kyriazopoulou-Panagiotopoulou S, Libbrecht M, Smith CL, Raha
D, et al. (2012) Ubiquitous heterogeneity and asymmetry of the chromatin
environment at regulatory elements. Genome Res 22: 1735–1747.
14. Wallerman O, Motallebipour M, Enroth S, Patra K, Bysani MS, et al. (2009)
Molecular interactions between HNF4a, FOXA2 and GABP identified at
regulatory DNA elements through ChIP-sequencing. Nucleic Acids Res 37:
7498–7508.
15. Beane J, Vick J, Schembri F, Anderlind C, Gower A, et al. (2011) Characterizing
the Impact of Smoking and Lung Cancer on the Airway Transcriptome Using
RNA-Seq. Cancer Prev Res (Phila) 4: 803–817.
16. Charge SB, Rudnicki MA (2004) Cellular and molecular regulation of muscle
regeneration. Physiol Rev 84: 209–238.
17. Florini JR, Magri KA, Ewton DZ, James PL, Grindstaff K, et al. (1991)
‘‘Spontaneous’’ differentiation of skeletal myoblasts is dependent upon autocrine
secretion of insulin-like growth factor-II. J Biol Chem 266: 15917–15923.
18. Molkentin JD, Olson EN (1996) Combinatorial control of muscle development
by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad
Sci U S A 93: 9366–9373.
19. Cao Y, Kumar RM, Penn BH, Berkes CA, Kooperberg C, et al. (2006) Global
and gene-specific analyses show distinct roles for Myod and Myog at a common
set of promoters. EMBO J 25: 502–511.
20. Reichow SL, Hamma T, Ferre-D’Amare AR, Varani G (2007) The structure
and function of small nucleolar ribonucleoproteins. Nucleic Acids Res 35: 1452–
1464.
21. Van Laere AS (2005) From QTL to QTN: Identification of a Quantitative Trait
Nucleotide Influencing Muscle Development and Fat Deposition in Pig.
Uppsala: Swedish University of Agricultural Sciences. 32 p.
22. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, et al. (2008)
Combinatorial patterns of histone acetylations and methylations in the human
genome. Nat Genet 40: 897–903.
23. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-
resolution profiling of histone methylations in the human genome. Cell 129:
823–837.
24. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, et al. (2002)
Active genes are tri-methylated at K4 of histone H3. Nature 419: 407–411.
25. Raghav SK, Waszak SM, Krier I, Gubelmann C, Isakova A, et al. (2012)
Integrative genomics identifies the corepressor SMRT as a gatekeeper of
adipogenesis through the transcription factors C/EBPb and KAISO. Mol Cell
46: 335–350.
26. Michal B, Mathieu M, Robert N (2007) FlexArray: A statistical data analysis
software for gene expression microarrays. Genome Quebec, Montreal, Canada
69.
Transcriptional Regulation Mediated by ZBED6
PLOS ONE | www.plosone.org 13 April 2014 | Volume 9 | Issue 4 | e94187
27. Blazejczyk M, Miron M, Nadon R (2007) FlexArray: A statistical data analysis
software for gene expression microarrays. Genome Quebec, Montreal, Canada.
28. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical
and powerful approach to multiple testing. Journal of the Royal Statistical
Society, Series B Methodological 57: 289–300.
29. Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, et al. (2005)
oPOSSUM: identification of over-represented transcription factor binding sites
in co-expressed genes. Nucleic Acids Res 33: 3154–3164.
30. Ho Sui SJ, Fulton DL, Arenillas DJ, Kwon AT, Wasserman WW (2007)
oPOSSUM: integrated tools for analysis of regulatory motif over-representation.
Nucleic Acids Res 35: W245–252.
31. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, et al. (2008) Model-based
analysis of ChIP-Seq (MACS). Genome Biol 9: R137.
32. Quinlan AR, Hall IM (2010) BEDTools: a flexible suite of utilities for comparing
genomic features. Bioinformatics 26: 841–842.
Transcriptional Regulation Mediated by ZBED6
PLOS ONE | www.plosone.org 14 April 2014 | Volume 9 | Issue 4 | e94187
